Predictive Oncology Inc

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes clinical testing and contract research services that include the application of AI. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within corporate. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Predictive Oncology Inc advances in cancer research and cost optimization

POAI's Q2 2024 performance reflects progress in research, technology, and cost optimization strategies.
While facing challenges in financial metrics, the company's focus on innovation and shareholder value creation positions it for long-term success.
Opportunities lie in leveraging AI capabilities, strategic partnerships, and revenue growth initiatives to drive future growth and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.

Company to host investor call and webcast today, November 14th, at 8:30am EDT Company to host investor call and webcast today, November 14th, at 8:30am EDT

Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

Predictive Oncology Inc announced that it has completed a multi-year study with UPMC Magee-Womens Hospital in Pittsburgh.  The science-driven company said the objective of the study was to evaluate the use of AI to build multi-omic machine learning (ML) models and test if these models can learn associations between the datasets and ovarian cancer patient short- and long-term survival.

Predictive Oncology completes AI-driven cancer study with UPMC Magee-Womens Hospital

PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study with UPMC Magee-Womens Hospital. The objective of the study was to evaluate the use of AI to build multi-omic machine learning (ML) models and test if these models can learn associations between the datasets and ovarian cancer patient short- and long-term survival.

Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital

C3.ai

QUALCOMM

With artificial intelligence (AI) showing no signs of cooling, we could see a $1.8 billion opportunity by 2030. AI is expected to help students learn better and faster, already profoundly impacting the medical industry and accelerating drug discovery.

3 AI Stocks Worth Buying Now for Multibagger Returns

Evolv Technologies Holdings

Remark Hlds

Artificial intelligence is here to stay, and as FOMO sets in, investors are flocking to little-known AI stocks. However, that doesn't mean investors aren't becoming weary and even skeptical about the way different companies are touting their use of AI.

3 AI Stocks to Buy That Aren't on Your Radar

Predictive Oncology, Inc. (NASDAQ:POAI ) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Director at LifeSci Partners Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Pamela Bush - Chief Business Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q2 2023 Earnings Conference Call.

Predictive Oncology, Inc. (POAI) Q2 2023 Earnings Call Transcript

Predictive Oncology reported its second-quarter financial results after the bell Thursday, including a significantly narrower loss than the same quarter of 2022.  The drug development company reported a loss of $0.98 per share, compared to $2.89 in the year-ago quarter.

Predictive Oncology dramatically narrows its quarterly loss in latest financial results

Company to host investor call and webcast today, August 10th, at 5:30pm EDT Company to host investor call and webcast today, August 10th, at 5:30pm EDT

Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update

EAGAN, Minn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2023 after the markets close on Thursday, August 10, 2023.

Predictive Oncology to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on Thursday, August 10, 2023

Lantern Pharma

Rekor Systems Inc

The bull market in artificial intelligence is just getting started. In fact, with the boom only set to accelerate, we may be looking at a $1.81 trillion opportunity by 2030, says Grand View Research.

3 AI Stocks to Buy Under $10 in August 2023

Ideanomics Inc

SoundHound AI Inc

The era of artificial intelligence is upon us. By 2030, AI is expected to contribute $15.7 trillion to the global economy.

7 AI Penny Stocks that Could Hit $5 Soon

Predictive Oncology Inc. (NASDAQ:POAI) announced that it has moved its corporate headquarters to its main laboratory facility in Pittsburgh, Pennsylvania. The science-driven company said the logistical initiative further strengthens its commitment to scientific discovery and growth potential.

Predictive Oncology moves company headquarters to Pittsburgh

Surrounded by world renowned universities and medical centers, Predictive Oncology is part of the next generation of Pittsburgh's innovation ecosystem

Predictive Oncology Announces Relocation of Corporate Headquarters to Pittsburgh

Predictive Oncology Inc. (NASDAQ:POAI) has announced the addition of biopharmaceutical finance industry veteran Andrew Einhorn to its business advisory board.  Einhorn is the chief financial officer at Danforth Advisors, where he helps build up life science companies using institutional knowledge and provides financial advisory services to public and privately held companies.

Predictive Oncology adds biopharmaceutical CFO Andrew Einhorn to business advisory board

Innodata

With the artificial intelligence boom gaining momentum, we're likely to see far more acquisitions for some of the top AI stocks to watch. For one, AI behemoths like Nvidia (NASDAQ: NVDA ), Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ), and Microsoft (NASDAQ: MSFT ) are exploring new ways to innovate, stay ultra-competitive, and ramp up revenue.

Big Tech on the Prowl: 3 Potential AI Stock Acquisition Targets

EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of biopharmaceutical finance veteran Mr. Andrew Einhorn to its Business Advisory Board.

Predictive Oncology Appoints Biopharmaceutical Finance Veteran Mr. Andrew Einhorn to its Business Advisory Board

Predictive Oncology Inc. (NASDAQ:POAI) has announced the appointment of Dr Bernard Harris Jr to its newly-formed Business Advisory Board (BAB). The company said Harris, who previously worked at NASA, serves as CEO and managing partner of Vesalius Ventures, Inc, a venture capital firm that supports and invests in early-to-mid-stage healthcare companies.

Predictive Oncology appoints Dr Bernard Harris Jr to Business Advisory Board

EAGAN, Minn., June 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of Dr. Bernard A. Harris, Jr. to its newly-formed Business Advisory Board (BAB).

Predictive Oncology Appoints Dr. Bernard A. Harris, Jr. to its Newly Formed Business Advisory Board

The Oncology Institute

The NASDAQ index led the market out of technical bear market territory. And if the rally is going to have legs, investors will know they have artificial intelligence ( AI ) to thank for it.

3 Penny Stocks That Have Game-Changing Technologies

ExScientia Ltd

Schrodinger 

A Deloitte report about artificial intelligence (AI) in the life sciences puts it bluntly. Big data is the new currency for biopharma firms.

3 Pharma Stocks That Will Boom Thanks to AI

Pamela Bush, Chief Business Officer of Predictive Oncology, to discuss advancing pipelines and using patient heterogeneity with AI to solve the missing link in drug discovery Pamela Bush, Chief Business Officer of Predictive Oncology, to discuss advancing pipelines and using patient heterogeneity with AI to solve the missing link in drug discovery

Predictive Oncology invited to present groundbreaking approach to drug discovery at the 2023 BIO International Convention

Predictive Oncology has updated investors on its use of artificial intelligence (AI) and machine learning and its extensive biorepository of tumor samples, CLI laboratory and GMP facility to accelerate oncologic drug discovery and development during the first three months of 2023 along with the release of its first quarter financial results. Predictive Oncology CEO Raymond Vennare pointed to a number of milestones achieved during the quarter, including ground-breaking partnerships and key appointments.

Predictive Oncology forges key partnerships to drive oncology drug development in 1Q

Predictive Oncology, Inc. (NASDAQ:POAI ) Q1 2023 Earnings Conference Call May 15, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Director at LifeSci Partners Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Pamela Bush - Chief Business Officer Conference Call Participants Michael Broadbent - Private Investor Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q1 2023 Earnings Conference Call.

Predictive Oncology, Inc. (POAI) Q1 2023 Earnings Conference Call Transcript

Company to host investor call and webcast today, May 15th, at 5:30pm EDT Company to host investor call and webcast today, May 15th, at 5:30pm EDT

Predictive Oncology Reports First Quarter 2023 Financial Results and Provides Business Update

Predictive Oncology Inc. (NASDAQ:POAI) said it has appointed healthcare commercial and business development veteran Dr Veena Rao to its board of directors. Dr Rao will replace David Smith, who is stepping down but will remain an advisor to the board and assume duties as legal counsel to the company.

News for Predictive Oncology Inc Stock (POAI)